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The Ets transcription factor, Fli-1 is activated in murine erythroleukemia and overexpressed in various human malignancies
including Ewing’s sarcoma, induced by the oncogenic fusion protein EWS/Fli-1. Recent studies by our group and others have
demonstrated that Fli-1 plays a key role in tumorigenesis, and disrupting its oncogenic function may serve as a potential
treatment option for malignancies associated with its overexpression. Herein, we describe the discovery of 30 anti-Fli-1
compounds, characterized into six functional groups. Treatment of murine and human leukemic cell lines with select
compounds inhibits Fli-1 protein or mRNA expression, resulting in proliferation arrest and apoptosis. This anti-cancer effect
was mediated, at least in part through direct inhibition of Fli-1 function, as anti-Fli-1 drug treatment inhibited Fli-1 DNA binding
to target genes, such as SHIP-1 and gata-1, governing hematopoietic differentiation and proliferation. Furthermore, treatment
with select Fli-1 inhibitors revealed a positive relationship between the loss of DNA-binding activity and Fli-1 phosphorylation.
Accordingly, anti-Fli-1 drug treatment signiﬁcantly inhibited leukemogenesis in a murine erythroleukemia model overexpressing
Fli-1. This study demonstrates the ability of this drug-screening strategy to isolate effective anti-Fli-1 inhibitors and highlights
their potential use for the treatment of malignancies overexpressing this oncogene.
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INTRODUCTION
The progression of cancer is a multistage process arising from the
additive or cooperative activities of multiple pathways, resulting
from the activation of proto-oncogenes and inactivation of tumor
suppressor genes. Delineation of the genetic processes involved in
the development of cancer will provide a better understanding of
how disruption of the homeostatic balance between proliferation,
differentiation and apoptosis leads to malignancy, as well as to
provide indications of potential therapeutic targets.
A well-studied example of multistage malignancy in mice is
erythroleukemia induced by different strains of Friend leukemia
virus. Studies using this cancer model have led to the identiﬁca-
tion of ﬂi-1, a member of the Ets family of transcription factors,
activated through retroviral insertional mutagenesis in 90% of
Friend Murine Leukemia virus (F-MuLV)-induced erythroleuke-
mias.
1,2 The constitutive activation of ﬂi-1 in erythroblasts leads to
a dramatic shift in the Epo/Epo-R signal transduction pathway,
blocks erythroid differentiation, and activates the Ras pathway,
ultimately resulting in massive Epo-independent proliferation of
erythroblasts.
3,4
In addition to Friend erythroleukemia, proviral integration at the
ﬂi-1 locus also occurs in leukemias induced by the Cas-Br-E virus
5
and Fli-1 aberrant expression is associated with chromosomal
abnormalities in humans. In Ewing’s sarcoma, a chromosomal
translocation generates a fusion of the 50 transactivation domain
of EWS with the 30 Ets domain of Fli-1. The resulting fusion
oncoprotein, EWS/Fli-1, acts as an aberrant transcriptional
activator with strong transforming capabilities.
6 The importance
of Fli-1 in the development of human leukemia, such as acute
myelogenous leukemia, has been demonstrated in studies
regarding the Tel transcription factor that interacts with Fli-1
through protein--protein interactions.
7 Fli-1 overexpression has
also been detected in various types of human sarcomas and
hematological malignancies.
8
Although Fli-1 overexpression has been detected in a wide
range of malignancies, the speciﬁc role of Fli-1 in tumorigenesis
has remained unclear. Our group has recently demonstrated that
RNAi-mediated downregulation of Fli-1 in both human and
murine erythroleukemias results in growth inhibition and rapid
cell death in vitro.
9 This observation is also supported by another
report in which downregulation of Fli-1 in murine erythroleukemia
results in massive cell death associated with downregulation of
several previously identiﬁed and novel Fli-1 target genes.
10
Together, this data strongly suggests that Fli-1 overexpression is
vital in maintaining the malignant phenotype and Fli-1 may serve
as a potential therapeutic target in a number of human
malignancies. In this study, using a sensitive screening assay, we
have identiﬁed 30 small molecules/compounds capable of
inhibiting Fli-1 expression and function. Herein, we describe the
capacity of select drugs to inhibit the expression and/or
transactivational activity of Fli-1 in several murine and human
malignancies resulting in inhibition of cell growth and apoptosis in
vitro and inhibition of leukemic progression in an F-MuLV-induced
erythroleukemia mouse model in vivo.
MATERIALS AND METHODS
Cell lines
Murine Friend virus-induced erythroleukemic cell lines DP17-17, CB3,
human erythroleukemic cell line HEL, and 293T cells were maintained in
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Drug screening
A schematic representation for Fli-1 drug screening is shown in Figure 1.
A DNA fragment selected by CAST containing two Fli-1 binding sites was
cloned into the pGL4.28 luciferase reporter (Promega, Madison, WI, USA)
containing a minimal promoter, designated Fli-Lu. Construction of the
expression vector, MSCV-EWS/Fli-1, was described previously.
9 Fli-Lu was
transiently transfected with the MSCV-EWS/Fli-1, MSCV empty vector or
CMV-Lu into 293T cells using Lipofectamine 2000 (Invitrogen, Burlington,
Canada). Cells were treated with compounds from various libraries 34h
post-transfection and screened for efﬁcient downregulation of luciferase
activity. Lead anti-Fli-1 compounds were chosen for their ability to reduce
luciferase activity by at least 50%.
Immunoblotting and antibodies
Cells were lysed with radio immunoprecipitation assay buffer (0.5%
Nonidet P-40, 50mM Tris HCl (pH 8.0), 120mM NaCl, 50mM NaF, plus 1mM
Na3VO4, 10g/ml aprotinin, 100g/ml leupeptin and 10mM phenylmethyl-
sulfonyl ﬂuoride). 40mg lysates were fractioned by SDS-Polyacrylamide gel
electrophoresis and transferred to a polyvinylidene ﬂuoride membrane
(Immobilon-P, Millipore, Billerica, MA, USA). The following antibodies were
used: Gata-1, SHIP-1 and Fli-1 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA); b-actin (Sigma-Aldrich, Oakville, Canada); Bcl-2 (Cell signaling,
Beverly, MA, USA) and goat-anti-mouse and goat anti-rabbit HRP-
conjugated secondary antibodies (Promega). CB3 cell lysates treated with
calcimycin (0.5mM) and cantharidin acid (Can A) (1.0mM) for 24h were
immunoprecipitated overnight at 41C using the Fli-1 antibody, and
washed three times. Fli-1 protein was resolved on SDS-Polyacrylamide gel
electrophoresis, transferred to a polyvinylidene ﬂuoride membrane
(Immobilon-P, Millipore), and immunoblotted using the phospho-threo-
nine (42H4) mouse antibody (Cell Signalling, Danvers, MA, USA).
RNA extraction and northern blotting
Total RNA preparation and northern blotting was performed as previously
described.
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Cell proliferation assays
Cancer cell lines CB3, HEL, A-673 and DP17-17 infected with MigR1-Fli-1
retrovirus
11 (1 10
4) were plated in triplicate and treated with the
indicated concentration of anti-Fli-1 drugs prepared from a 10mM stock
solution dissolved in DMSO. The Trypan-blue exclusion assay was
performed at 24-hour intervals for the Trypan-blue exclusion assay. Data
is representative of three independent experiments.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were isolated from HEL cells using the method described
previously.
11 Single-stranded oligonucleotides containing a Fli-1 binding site
located on the SHIP-1 promoter, 50-CCTGAAACAGGAAGTCAGTCAG-30,w e r e
radioactively-labeled (g-
32P)ATP with T4 polynucleotide kinase (New England
Biolabs, Pickering, Canada), puriﬁed using NUCTrap probe puriﬁcation columns
(Agilent Technologies, Santa Clara, CA, USA), annealed by boiling for 2min and
cooled at room temperature for 1h. For competition assays, 100-fold excess
cold single-stranded oligonucleotides were added. Fli-1 or c-Myc antibodies
(2ml; Santa Cruz Biotechnology) were used for the supershift assay. Samples
were electrophoresed on a 5% acrylamide gel in 0.5  TBE buffer.
Chromatin immunoprecipitation (ChIP) and quantitative PCR
HEL cells (1 10
8) were washed twice with PBS (Gibco) and crosslinked
with 1% formaldehyde at 371C for 15min, followed by addition of 125mM
glycine for 5min at room temperature. Fixed cells were washed in PBS and
incubated on ice for 50min in swelling buffer (20mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) pH 7.9, 10mM KCl, 1mM EDTA,
10% glycerol, 1mM DTT, 0.5mM phenylmethylsulfonyl ﬂuoride (PMSF),
0.1mM Na3VO4). Cells were homogenized on ice using a Dounce homo-
genizer, nuclei were pelleted by centrifugation, resuspended in lysis buffer
(10mM Tris-HCl pH 8.0, 140mM NaCl, 0.025% NaAzide, 1% TritonX-100,
0.1% SDS, 1mM DTT, 0.5mM PMSF, 0.1mM Na3VO4, 1% deoxycholate) and
sonicated using the Branson250 Soniﬁer, followed by centrifugation.
Fragmented chromatin was pre-cleared by incubation on ice with ProteinA
sepharose beads for 1h. A chromatin aliquot was removed for input control.
Immunoprecipitations were performed overnight at 41Cw i t h2 mg of Fli-1
(Santa Cruz Biotechnology) or nonspeciﬁc normal rabbit immunoglobulin G
(IgG; Promega) antibody. ProteinA sepharose beads were added and
incubation continued for 1h. Precipitates were washed once in 0.1% SDS,
1% TritonX-100, 2mM EDTA, 150mM NaCl, 20mM Tris-HCl; four times in
0.1% SDS, 1% TritonX-100, 2mM EDTA, 500mM NaCl, 20mM Tris-HCl; once
in 250mM LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris-HCl; three
times in TE buffer, and extracted by adding 200ml each of 1% SDS and
100mM NaHCO3. NaCl was added to a ﬁnal concentration of 300mM and
incubated overnight at 651C to reverse crosslinking. DNA was incubated
with proteinase K at 501C for 2h, puriﬁed with phenol chloroform and
resuspended in TE buffer. PCR was performed to amplify a SHIP-1 promoter
fragment containing the Fli-1 binding site, as previously described.
11
Primer forward: 50-CATGCCTTTGGCCTATTCAC-30, Reverse: 50-TGAGTGCCT
GAAACAGGAAGT-30. ChIP was quantiﬁed using the real-time PCR Qiagen
QuantiFast SYBR green PCR kit (Qiagen, Mississauga, Canada). The level of
SHIP-1 enrichment is expressed as the percentage of input chromatin
precipitated by Fli-1 or control IgG antibodies.
Tumor induction and in vivo drug studies
Viral supernatants from NIH-3T3 cells containing F-MuLV clone 57
1 were
harvested and frozen at --801C. Newborn mice were inoculated by
intraperitoneal F-MuLV (clone 57) injections with 100ml, 3000 focus-forming
units, within 48h of birth. Six weeks post infection, leukemic mice were
treated every other day for a total of six injections with peruvoside,
camptothecin (CPT), calcimycin, Can A (1mg/kg) or DMSO, and monitored for
signs of disease. Hematocrit values were measured by tail blood collection in
200ml heparinized capillary tubes (Drummond Scientiﬁc, Broomall, PA, USA),
centrifugation at 100 g for 10min, and evaluated using a hematocrit gauge.
All animal studies followed the institutional guidelines.
Survival and statistical analysis
Mice survival rates were computed and plotted according to the
nonparametric Kaplan- -Meier analysis. Statistical analysis was performed
using the two-tailed student’s t-test with signiﬁcance considered at Po0.05
by analysis of variance using Origin 3.5 software (Microcal Software,
Northampton, MA, USA).
Figure 1. Schematic representation of the Fli-1 drug-screening
strategy. Fli-Lu: Multiple copies of the Fli-1 consensus-binding
site (FB site) cloned upstream a minimal promoter immediately
upstream the luciferase gene. MSCV-EWS/Fli-1: EWS/Fli-1 gene cloned
into the MSCV retroviral vector. CMV-Lu: Luciferase gene driven
by the CMV promoter. Fli-1--Lu was co-transfected with either
MSCV-EWS/Fli-1 or CMV-Lu into 293T cells. Cells were treated with
various drugs 34h post transfection and screened for efﬁcient
downregulation of luciferase activity.
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Isolation of EWS/Fli-1 inhibitors from known small molecule/
compound libraries
To identify small molecules/compounds capable of inhibiting the
transactivation ability of Fli-1, luciferase assays were designed
using a vector with the Fli-1 Ets DNA binding site
9 cloned in front
of a minimal promoter, immediately upstream of the luciferase
reporter gene, designated Fli-1--Lu (Figure 1). The oncoprotein,
EWS/Fli-1, functions as a strong transcriptional activator compared
with Fli-1 alone, and possesses a strong transforming ability
mediated through the Fli-1 30 Ets domain.
12 EWS/Fli-1 exogenous
expression results in more robust luciferase activity compared
with Fli-1 alone.
9 Accordingly, the EWS/Fli-1 expression vector,
MSCV-EWS/Fli-1, was used for the screening assay in lieu of Fli-1.
The Fli-1--Lu construct was co-transfected with the EWS/Fli-1 vector
into 293T cells (Figure 1). 293T cells co-transfected with Fli-1--Lu and
MSCV empty vector or with the CMV-Lu luciferase vector driven by
the CMV constitutively active promoter, served as negative controls
compulsory for the exclusion of drugs that inhibit luciferase activity
through an indirect pathway independent of Fli-1 activity.
Screening experiments were conducted in high-throughput
formats using criteria to deﬁne positive hits as described
previously.
13,14 To this end, we employed biologically and
pharmacologically active compounds, natural products and
marketed drugs distributed in the LOPAC collection (1280
samples, SIGMA), Prestwick Chemical Library (1200 samples,
Prestwick Chemical) and Spectrum collection (2000 samples,
MicroSource). Screening the above libraries led to the identiﬁca-
tion of 30 compounds that efﬁciently downregulated EWS/Fli-1-
driven luciferase activity by at least 50%, in three independent
experiments. Lead compounds were clustered into six distinct
functional groups (full list in Table 1). The original screening was
performed at a concentration of 5mM, repeating a similar
screening at lower concentrations revealed that the majority of
the lead compounds have an IC(50) ranging between 0.165 and
5.62mM (Table 1). The six functional drug groups identiﬁed in our
study are classiﬁed as follows:
Group I - Cardenolides. Cardenolides also called cardiotonic
steroids, are potent inhibitors of Naþ/Kþ-ATPase and have
known anti-cancer properties.
15 We identiﬁed all ten known
Cardenolides as inhibitors of EWS/Fli-1 transactivation ability.
Peruvoside was chosen from this group for its use in the treatment
for congestive heart failure and has the lowest IC(50).
Group II - Calcium ionophores. These are used to increase
intracellular Ca
2þ levels in intact cells. The best example is
calcimycin (A23187), which induces differentiation of erythro-
leukemic cells through unknown pathways.
16 Out of the ﬁve
calcium ionophores identiﬁed, calcimycin displayed the greatest
Fli-1 inhibitory effect.
Group III - Topoisomerase I inhibitors. It has been previously shown
that CPT, a topoisomerase I inhibitor, inhibits Friend virus-induced
erythroleukemia progression.
17 CPT indeed acts as a potent inhibitor
of EWS/Fli-1 transcriptional activity at very low concentrations.
Group IV - Protein synthesis inhibitors. Two inhibitors of protein
synthesis inhibitors were identiﬁed to block EWS/Fli-1 activity at
very low concentrations.
Group V - Chemotherapeutic drugs. Four chemotherapeutic drugs
were identiﬁed in our screening. Etoposide and Dactinomycin,
known potent topoisomerase inhibitors, inhibit EWS/Fli-1 activity
at nanomolar concentrations. These drugs are in current use for
the treatment of Ewing’s sarcoma.
18
Group VI - Other inhibitors. This group consists of eight drugs that
exert anti-Fli-1 activity at various concentrations, not ﬁtting the
above classiﬁcations.
To examine the ability of the lead anti-Fli-1 compounds to
inhibit Fli-1 in cancer cells overexpressing Fli-1, representative
drugs with different biological activities from group I, II and III,
namely peruvoside, calcimycin and CPT, were chosen for
further anti-Fli-1 drug analysis. Comparison of speciﬁcity, potency
and mechanisms of action for each member would facilitate
the selection of lead anti-Fli-1 compounds for potential use as
single drugs or, if appropriate, combined formulations with
potentially enhanced efﬁcacy. This study did not include the
investigation of compounds from group IV (protein synthesis
inhibitors), as in addition to anti-Fli-1 activity these drugs may
obtain the ability of broad, nonspeciﬁc protein inhibition of
other factors having a role in Fli-1--associated malignancies, and
group V (chemotherapeutic drugs), as the clinical efﬁcacy of these
drugs has already been demonstrated, as well as group VI, as
inhibition is detected at high dosages, where toxicity may be of
concern.
Similarly, additional luciferase assays were performed to conﬁrm
the level of EWS/Fli-1 inhibition through treatment with peruvo-
side, CPT and Calcimycin. Drugs from groups I--III also inhibited
EWS/Fli-1 activity in an Ewing’s sarcoma cell line leading to a block
in cellular proliferation and induction of apoptosis (data not
shown, to be published in an independent study).
Table 1. Classiﬁcation of lead anti-Fli-1 compounds
Drug classes Number of
drugs
Drug name Effective dose
(mM) IC(50)
a
Cardenolides 10 Peruvoside, digitoxin, dihydroouabain, quabain, strophanthidin, proscillaridin A, cymarin,
convalatoxin, gitioxin, lanatoside C
0.165- -0.33
Calcium
ionophores
5 Calcimycin, alexidine dihydrochloride, gossypol-acetic acid complex, oligomycin A,
thapsigargin
0.66- -1.33
Topoisomerase I
inhibitors
1 Camptothecin 0.33
Protein synthesis
inhibitors
2 Emetine, anisomycin 0.165- -0.66
Chemotherapeutic
drugs
4 Etoposide, dactinomycin, cycloheximide, puromucine dihydrochloride, 0.66- -2.66
Others 8 Cedrelone, 5-azacytidine, anthothecol, cephaline, dihydrochloride heptahydrate, helveticoside,
deacetoxy-7-oxogedunin, pyrvinion pamoate, cantharidin acid
0.66- -5.62
Compound library screening resulted in the identiﬁcation of six drug classes with the indicated number in each class.
aIC(50) was calculated as the lowest
drug concentration resulting in a 50% reduction of EWS/Fli-1 luciferase activity. Column 3 displays one example of each inhibitor drug class. Column 4
displays the calculated range of effective dose response for each class.
Fli-1 inhibitor identiﬁcation and characterization
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Fli-1 overexpressing erythroleukemic cells
To investigate whether the identiﬁed anti-EWS/Fli-1 compounds
also inhibit endogenous Fli-1 expression or activity, and as a result
exert the toxic effects previously observed through RNAi-
mediated Fli-1 downregulation,
9,10 Fli-1 overexpressing murine
erythroleukemic CB3 cells
2 were treated with representative drugs
from groups I--III. Although treatment with peruvoside did not
signiﬁcantly affect the growth of CB3 cells in culture, CPT and
calcimycin drastically inhibited the proliferation of these cells in a
dose-dependent manner (Figure 2). Interestingly, only treatment
with CPT reduced Fli-1 expression in a dose-dependent manner
(Figure 2c); however, it did not affect transcription levels
(Figure 2d), suggesting post-transcriptional regulation.
Growth inhibition by treatment with groups I--III drugs also
occurs in the Fli-1 overexpressing human erythroleukemia cell line
termed HEL (Figures 3a--c). However, although treatment with
peruvoside in CB3 cells had only a minor inhibitory effect on
proliferation leaving Fli-1 protein expression unaltered (Figure 2a),
treatment of HEL cells signiﬁcantly inhibited proliferation and
signiﬁcantly reduced Fli-1 protein levels at a concentration of
0.1mM (Figure 3a). Similarly, treatment of CB3 cells with other lead
compounds from group I, digitoxin, quabain and strophanthidin
did not affect growth; however, treatment of HEL cells again
resulted in a marked growth inhibition (data not shown). These
results are consistent with the previous observation demon-
strating a weak Naþ/Kþ-ATPase activity and reduced drug
penetration in mice compared with human cells.
19 Treatment
of HEL cells with peruvoside also resulted in downregulation
of Fli-1 mRNA levels (Figure 3d), suggesting inhibition of Fli-1
transcription.
To determine whether the anti-proliferative effect of lead anti-
Fli-1 drug treatment was directly mediated through inhibition of
Fli-1, we investigated the effects of drug treatment in DP17-17
erythroleukemic cells with endogenous Fli-1 and ectopic Fli-1
overexpression. This cell line, derived from murine erythroleuke-
mia induced by Friend virus, overexpresses another ETS transcrip-
tion factor
20 but expresses endogenous Fli-1 (Figure 4a). DP17-17
cells were transduced with Fli-1-expressing retrovirus resulting in
ectopic Fli-1 overexpression compared with the parental line
(Figure 4a). Treatment of Fli-1 overexpressing DP17-17 cells with
calcimycin and CPT led to a marked growth inhibition only at
higher dosages (Figures 4b and c). Treatment with lower doses
of calcimycin (0.5mM) and CPT (0.1mM) somewhat reduced
the survival of these cells, albeit at a lower level compared
with vector alone treated cells displaying marked inhibition
with the same drug concentration (Figures 4b and c). The
ectopic overexpression of Fli-1, or increase in functional protein
Figure 2. Effect of anti-Fli-1 drugs on the proliferation of the erythroleukemia cell line CB3. CB3 cells (1 10
4) were plated in triplicate and
treated with the indicated concentrations of (a) peruvoside (Per), (b) calcimycin (Cal), (c) CPTor vehicle DMSO control for 3 days (D1-3). Viable
cells were counted on the indicated days using trypan blue exclusion assay. Fli-1 expression was analyzed 24h post drug treatment. (d) CB3
cells were treated with the indicated concentrations of CPT for 24h and subjected to northern blot analysis using a ﬂi-1 cDNA probe.
Fli-1 inhibitor identiﬁcation and characterization
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Blood Cancer Journal & 2012 Macmillan Publishers LimitedFigure 3. Effect of anti-Fli-1 drugs on the proliferation of human erythroleukemia cell line HEL. HEL cells (1 10
4) were plated in triplicate and
treated with the indicated concentrations of (a) peruvoside (Per), (b) calcimycin (Cal), (c) CPT or the vehicle control DMSO for 4 days (D1-4).
The viable cells were counted on the indicated days using trypan blue exclusion assay. At 24h post drug treatment the leukemic cells
were subjected to western blot analysis using an anti-Fli-1 antibody. (d) HEL cells were treated with the indicated concentrations of
peruvoside for 24h and subjected to northern blot analysis using a ﬂi-1 cDNA probe.
Figure 4. Ectopic Fli-1 overexpression in erythroleukemic cells partially overcome growth inhibition induced by anti-Fli-1 drug treatment.
(a) Increased levels of Fli-1 protein expression in the murine erythroleukemic cell line DP17-17, infected with retrovirus expressing
Fli-1 (b-- c) DP17-17 cell transduced with the vector control or Fli-1 expressing virus were treated with the indicated concentrations
of (b) calcimycin (Cal), (c) CPT or the vehicle control DMSO for 3 days, and viable cells were counted on the indicated days using trypan
blue exclusion assay.
Fli-1 inhibitor identiﬁcation and characterization
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of lower dosages. This data further supports the role of Fli-1 in
leukemic proliferation and demonstrates that the representative
anti-Fli-1 drugs exert their toxic effects at least in part through
inhibition of Fli-1.
Selective anti-Fli-1 drugs induce Fli-1 downregulation and/or block
its DNA binding activity
As described above, although CPT and peruvoside downregulate
the expression of Fli-1, calcimycin blocks proliferation of Fli-1
overexpressing leukemic cells without effecting the protein levels
of this oncogene (Figures 2 and 3). We hypothesized that
calcimycin-dependent growth inhibition may result from its ability
to inhibit the binding of Fli-1 to its target gene DNA. To test this
hypothesis, EMSA were performed using nuclear extracts from HEL
cells and labeled oligonucleotides containing two tandem known
Fli-1 Ets DNA-binding sites.
11 Two dominant bands (Fli-1A and
Fli-1B) were detected and supershifted by the addition of Fli-1
antibody, although the addition of c-Myc antibody did not result
in supershift (Figure 5a). The Fli-1A band was supershifted more
efﬁciently than the Fli-1B band although both bands disappeared
when nuclear extracts were incubated with cold competitor.
Figure 5. Binding of Fli-1 to target gene DNA is inhibited by anti-Fli-1 drug treatment. (a) Nuclear extracts from drug treated (calcimycin 0.5mM,
CPT 0.1mM) and untreated HEL cells were incubated with g-
32P-labelled oligonucleotides containing a Fli-1-binding site, in the presence or
absence of Fli-1 antibody and subjected to EMSA. Addition of the c-Myc antibody was used as a negative control (lane 5). Competition assays
were performed in the presence of 100--fold excess unlabeled oligonucleotides (cold competitor). Arrows indicate the position of Fli-1-speciﬁc
bands, Fli-1A and Fli-1B. (b) Inhibition of Fli-1 through anti-Fli-1 drug treatment results in protein upregulation of the Fli-1 target gene SHIP-1
11
in HEL cells, as indicated by western blot. (c) Reduced binding of Fli-1 to the SHIP-1 promoter (lane 1) in HEL cells treated with anti-Fli-1 drugs
(calcimycin 0.5mM, CPT 0.1mM, peruvoside 0.1mM), as determined by ChIP using 2mg Fli-1 or rabbit IgG antibody. (d) ChIP quantitative-PCR
using Fli-1 and rabbit IgG antibodies illustrating reduced Fli-1 chromatin occupancy on the SHIP-1 promoter in HEL cells treated with the
indicated anti-Fli-1 drugs. The level of SHIP-1 enrichment is expressed as the percentage of input chromatin precipitated by Fli-1 or control IgG
antibodies. (e) Similar to SHIP-1, inhibition of Fli-1 resulted in upregulation of Gata-1 protein expression in HEL and CB3 cells treated with the
indicated dosages of anti-Fli-1 drugs or DMSO control. Treatment of CB3 and HEL cells with the indicated concentration of (f) calcimycin and
(g) Can A inhibits the protein expression of PKCd in a dose-dependent manner. (h) CB3 and HEL cells treated with calcimycin (0.5mM) and
Can A (1.0mM) display reduced levels of phosphorylated Fli-1 protein, as detected by western blot analysis using an anti-threonine antibody.
Anti-Fli-1 antibody was used to demonstrate total protein levels.
Fli-1 inhibitor identiﬁcation and characterization
Y-J Li et al
6
Blood Cancer Journal & 2012 Macmillan Publishers LimitedTo examine the effect of anti-Fli-1 drugs on DNA binding, nuclear
extracts from HEL cells treated with CPT (0.1mM) and calcimycin
(0.5mM) for 24h were subjected to EMSA. As CPT reduces the
levels of Fli-1 in HEL cells (Figure 3), reduced binding to Fli-1A and
Fli-1B bands and consequently a weaker supershift was detected
(Figure 5a). Similarly, cells treated with calcimycin displayed a
lower intensity of Fli-1A and Fli-1B bands as well as the Fli-1
supershifted band (Figure 5a).
The EMSA results demonstrate the ability of calcimycin to
signiﬁcantly lower the DNA-binding activity of Fli-1. Subsequently,
we examined the effect of anti-Fli-1 drug treatment on the
expression of known Fli-1 target genes, such as SHIP-1.
11 SHIP-1 has
been identiﬁed in our laboratory as a direct target gene, negatively
regulated by Fli-1.
11 Reduced expression of SHIP-1 correlates with
signiﬁcantly accelerated erythroleukemia progression in vitro and
in vivo.
11 Accordingly, treatment of the human erythroleukemia cell
line HEL with CPT, peruvoside and calcimycin at dosages previously
shown to inhibit cell growth (Figure 3), resulted in elevated levels
of SHIP-1 (Figure 5b). Inhibition of Fli-1 binding to the SHIP-1
promoter by CPT, peruvoside and calcimycin was also conﬁrmed
by ChIP assay, using a Fli-1 antibody and analyzed by PCR
amplifying a Fli-1-binding region within the SHIP-1 promoter.
11
Results in Figure 5c reveal that anti-Fli-1 drug-treated HEL cells
display a reduction in the binding of Fli-1 to its binding site on the
SHIP-1 promoter, compared with control DMSO-treated cells. ChIP
quantitative PCR (Figure 5d) also illustrated reduced Fli-1
chromatin occupancy on the SHIP-1 promoter. We also examined
the expression of Gata-1, a gene known to have a key role in
erythroid differentiation and proliferation, whose expression is
negatively regulated by Fli-1.
7 Accordingly, treatment of both HEL
and CB3 cells with each of the three anti-Fli-1 drugs upregulated
the expression of Gata-1 (Figure 5e).
Selective anti-Fli-1 drugs block phosphorylation of Fli-1 resulting
in inhibition of DNA binding
Calcimycin inhibits Fli-1 DNA binding without affecting its
expression levels (Figure 2b). Both isoforms of Fli-1, p51 and p48,
are phosphorylated, on serine residues, in part by protein
phosphatase 2A (PP2A) in the Jurkat human T-cell leukemia cell
line.
21 Fli-1 is also phosphorylated at threonine 312 by protein
kinase C delta (PKCd), which promotes its interaction with p300/
CREB-binding protein-associated factor and subsequent acetylation
in response to transforming growth factor beta.
22 Calcimycin may
alter Fli-1 phosphorylation status at speciﬁc sites, thereby affecting
its DNA-binding activity. To test this hypothesis, expression levels of
PKCd were detected in both CB3 and HEL cells treated with
calcimycin. Treatment with calcimycin downregulated PKCd protein
expression in a dose-dependent manner (Figure 5f). Interestingly,
Can A one of the class VI Fli-1 inhibitors identiﬁed in our drug
screen (Table 1) previously shown to inhibit PP2A,
21 also inhibits
PKCd expression (Figure 5g). Indeed, we have shown that both
calcimycin and Can A inhibit phosphorylation of Fli-1 in
erythroleukemic cells using a pan-speciﬁc-anti-threonine antibody
(Figure 5h). Taken together, this data suggests an important role for
phosphorylation in the regulation of Fli-1 activity.
Inhibition of leukemogenesis by in vivo anti-Fli-1 drug treatment
To demonstrate the effect of groups I--III drugs on in vivo cancer
progression, we utilized the Friend leukemia mouse model in
which Fli-1 overexpression is critical for the induction of this
disease.
2 Normal Balb/c mice display tolerance to treatment with
groups I--III drugs at dosages of 1mg/kg and 3mg/kg, without
signs of major cytotoxicity when administered for a period of 2
weeks (data not shown). Previous studies demonstrated that
erythroleukemia development, associated with ﬂi-1 activation, can
be detected as early as 4 weeks post-viral infection.
23 Treatment of
six-week old leukemic mice (n¼9/group) with groups I--III drugs
(1mg/kg) revealed a signiﬁcant reduction in tumor burden by CPT
and calcimycin, as supported by increased hematocrit values and
decreased spleen weights, compared with PBS or DMSO-treated
control mice (Figure 6a). Consistent with the weak growth
inhibitory effect observed with the treatment of peruvoside in
murine erythroleukemic cells (Figure 2a), we also detected an
inferior and less signiﬁcant inhibition effect by this drug in our
Figure 6. Inhibition of leukemogenesis by anti-Fli-1 drugs. (a) 6-week old mice, infected at birth with F-MuLV, were treated every other day
with the indicated drugs (1mg/kg), for a period of 2 weeks. At the end of drug treatment, mice were sacriﬁced, and characteristic indicators
of leukemia development, spleen weights and hematocrit levels were measured. Treatment with representative drugs from groups I-III
signiﬁcantly delayed leukemia development, associated with increased hematocrit values and reduced spleen size. Statistical signiﬁcance
(P value) is shown for each group. (b) F-MuLV-infected mice treated at day 35 post-infection with calcimycin (Cal; 1mg/kg), Can A (1mg/kg)
or DMSO and observed for the development of leukemia. All DMSO control mice died 70 days post viral infection; 5 days later (75 dpi)
anti-Fli-1 drug-treated mice were killed for purposes of comparison.
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shown to inhibit Fi-1 phosphorylation (Figure 5h), we have also
shown that treatment of F-MuLV-infected mice with these drugs
signiﬁcantly extended the survival of these mice (Figure 6b).
DISCUSSION
Recent studies from our group and others have demonstrated that
RNAi-mediated Fli-1 downregulation in both murine and human
erythroleukemia blocks proliferation and induces apoptosis.
9,10
These results, for the ﬁrst time, demonstrate the importance of
Fli-1 in the induction and progression of both mouse and human
erythroleukemia. Aberrant regulation of Fli-1 is also observed in a
wide variety of human and murine disorders, suggesting that
targeting Fli-1 for inhibition may be a potent treatment strategy
for cancers overexpressing this oncogene. In this study, we have
identiﬁed 30 compounds, classiﬁed into six functional groups that
block Fli-1 transactivation ability, and associated with growth
inhibition in leukemic cell lines overexpressing this oncogene.
More importantly, treatment with representative anti-Fli-1 com-
pounds from drug classes I--III also inhibited Friend virus-induced
erythroleukemia development.
Among 30 anti-Fli-1 drugs identiﬁed in our study, 10 can be
characterized as glycosides, a drug class known for their potent
ability to inhibit Naþ,K þ-ATPase, contributing to their anti-
cancer properties. Some members of this group like digoxin and
ouabain have strong differentiation effects on both murine and
human erythroleukemic cells.
24,25 Within this group, the activity
and function of peruvoside in cancer is undetermined, as this drug
is currently used for the treatment of heart failure. We have shown
that treatment with peruvoside downregulates Fli-1 protein
expression in humans (Figure 3a) at the transcriptional level
(Figure 3d), not in murine erythroleukemic cells (Figure 2a). This
result is consistent with weaker Naþ/Kþ-ATPase channel activity
reported in murine cells.
19 Although treatment of F-MuLV-induced
erythroleukemic mice with peruvoside has minimal effects on the
induction and progression of disease, this drug may be more
efﬁcient for the treatment of human cancers overexpressing Fli-1.
Although peruvoside inhibits Fli-1 expression at the transcriptional
level, CPT inhibits expression at the post-transcriptional level (Figures
2c and 3c). CPT has been characterized as a potent topoisomerase I
inhibitor.
26 A previous study has shown that the degree to which
glycosides inhibit cancer cell growth correlates with the ability to
inhibit Topoisomerase II-activity.
27 It has been previously shown that
glycosides also obtain the ability to inhibit Topoisomerase I.
28 This
suggests that inhibition of Fli-1 by peruvoside and CPT are likely
mediated through the inhibition of topoisomerases. In accordance
with weak inhibition observed in murine cells treated with glyco-
sides, our results suggest that CPT and Peruvoside utilize different
pathways to alter topoisomerase activity.
Etoposide, another potent topoisomerase inhibitor, can be
classiﬁed within the chemotherapeutic group of drugs, named
group V. Including Etoposide, 12 out of 30 anti-Fli-1 drugs
identiﬁed in our screening strategy are potent inhibitors of
topoisomerases. Thus, cancers in which Fli-1 overexpression has a
key role in survival and proliferation, topoisomerase inhibitors may
exert anti-cancer activity, in part, through inhibition of this
transcription factor. This observation suggests that our drug-
screening strategy serves as a strong assay for the identiﬁcation of
additional and more potent members of anti-topoisomerase drugs
for the treatment of cancer.
Five calcium ionophores with potent anti-Fli-1 activity were
identiﬁed in our drug screening, suggesting the importance of
intracellular Ca
þ levels on the regulation of Fli-1 transactivation
ability. Although calcimycin is known to induce differentiation and
promote erythroleukemic cell death,
16,29 the mechanism of its
anti-cancer activity is yet to be identiﬁed. As downregulation of
Fli-1 in erythroleukemic cells induces differentiation and cell
death,
9 calcimycin likely induces these events by inhibiting Fli-1
transactivation ability. Indeed, calcimycin inhibited Fli-1 and EWS/
Fli-1 transactivation ability without affecting their expression.
These results were supported by EMSA and ChIP assays, which
revealed reduced DNA binding of Fli-1 in erythroleukemic cells
treated with calcimycin. As expected, these drugs also upregu-
lated the expression of the anti-proliferative Fli-1 target gene
gata-1 and SHIP-1. Thus, calcimycin and likely other anti-Fli-1
drugs inhibit Fli-1 transactivation ability through a mechanism
that does not involve downregulation of this oncoprotein.
It has been shown that Fli-1 is phosphorylated at speciﬁc sites,
likely altering its transactivational activity.
21,22 In this study, we
have shown that reduced Fli-1 DNA binding by calcimycin is
associated with a dramatic downregulation of PKCd expression, a
kinase known to phosphorylate Fli-1 at threonine 312.
22 Another
striking observation in our study was that cantharidin, a known
PP2A phosphatase inhibitor,
21 also inhibits PKCd expression in
erythroleukemic cells. Indeed, both calcimycin and Can A block
phosphorylation on the threonine residue of erythroleukemic cells
in vitro and, accordingly, administration of these drugs in mice
inhibited erythroleukemia development. These results demon-
strate that inhibition of Fli-1 phosphorylation, mediated by PKCd
downregulation, blocks Fli-1 transactivation ability through
restriction of its DNA-binding capacity. The above observations
also suggest that this drug-screening strategy is a potent method
to uncover transcription factor function, as we have demonstrated
in the case of Fli-1. Moreover, our results also raise the possibility
that several uncharacterized anti-Fli-1 drugs may alter other
aspects of Fli-1 activity that could further provide insight into the
role of this transcription factor in oncogenesis and development.
In summary, our mechanistic drug-screening strategy aimed at
targeting EWS/Fli-1 has led to the identiﬁcation of 30 compounds
capable of inhibiting the function of this fusion oncoprotein.
Selected compounds from three distinct drug classes blocked the
expression and/or the activity of Fli-1 in leukemic cells resulting in
cell growth arrest and apoptosis. In a mouse model of erythroleu-
kemia overexpressing Fli-1, these drugs have also demonstrated
strong anti-leukemic activity. Taken together, these results revealed
the potential and importance of targeting Fli-1 activity for the
improvement of cancer therapy, and have identiﬁed a simple and
sensitive strategy to identify potent anti Fli-1 compounds for the
treatment of various cancers overexpressing Fli-1.
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